Healthcare [ 7/13 ] | Medical Devices [ 107/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 8, 24 | 0.5 Increased by +47.06% | 0.43 Increased by +16.28% |
| Oct 26, 23 | 0.5 Increased by +78.57% | 0.34 Increased by +47.06% |
| Jul 27, 23 | 0.34 Increased by +100% | 0.23 Increased by +47.83% |
| Apr 27, 23 | 0.17 Increased by +112.5% | 0.15 Increased by +13.33% |
| Feb 9, 23 | 0.34 Increased by +100% | 0.27 Increased by +25.93% |
| Oct 27, 22 | 0.28 Increased by +27.27% | 0.24 Increased by +16.67% |
| Jul 28, 22 | 0.17 Decreased by -10.53% | 0.19 Decreased by -10.53% |
| Apr 28, 22 | 0.08 Increased by 0% | 0.13 Decreased by -38.46% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 1.03 B Increased by +26.9% | 256.3 M Increased by +179.19% | Increased by +24.78% Increased by +120.01% |
| Sep 30, 23 | 975 M Increased by +26.69% | 120.7 M Increased by +19.27% | Increased by +12.38% Decreased by -5.86% |
| Jun 30, 23 | 871.3 M Increased by +25.15% | 115.9 M Increased by +127.7% | Increased by +13.3% Increased by +81.94% |
| Mar 31, 23 | 741.5 M Increased by +17.92% | 48.6 M Decreased by -50.05% | Increased by +6.55% Decreased by -57.64% |
| Dec 31, 22 | 815.2 M Increased by +16.76% | 91.8 M Increased by +573.2% | Increased by +11.26% Increased by +505.28% |
| Sep 30, 22 | 769.6 M Increased by +18.36% | 101.2 M Increased by +42.74% | Increased by +13.15% Increased by +20.59% |
| Jun 30, 22 | 696.2 M Increased by +16.99% | 50.9 M Decreased by -19.08% | Increased by +7.31% Decreased by -30.83% |
| Mar 31, 22 | 628.8 M Increased by +24.51% | 97.3 M Increased by +141.44% | Increased by +15.47% Increased by +93.9% |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.